V. A. Carozzi, A. Canta, and A. Chiorazzi, Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?, Neurosci Lett. 2 juin, vol.596, pp.90-107, 2015.

, Institut National du Cancer, 10e édition « les cancers en France, 2017.

J. A. Boyette-davis, E. T. Walters, and P. M. Dougherty, Mechanisms involved in the development of chemotherapy-induced neuropathy, Pain Manag, vol.5, issue.4, pp.285-96, 2015.

D. I?ycki, A. A. Niezgoda, M. Ka?mierczak, T. Piorunek, N. I?ycka et al., Chemotherapy-induced peripheral neuropathy -diagnosis, evolution and treatment, Ginekol Pol, vol.87, issue.7, pp.516-537, 2016.

H. Starobova and I. Vetter, Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy, Front Mol Neurosci, vol.10, p.174, 2017.

J. Addington and M. Freimer, Chemotherapy-induced peripheral neuropathy: an update on the current understanding, vol.5, 2016.

D. L. Hershman, C. Lacchetti, R. H. Dworkin, E. Smith, J. Bleeker et al., Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers, J Clin Oncol. 20 juin, vol.32, issue.18, pp.1941-67, 2014.

S. Dasari and P. B. Tchounwou, Cisplatin in cancer therapy: molecular mechanisms of action, Eur J Pharmacol, vol.740, pp.364-78, 2014.

E. S. Mcdonald and A. J. Windebank, Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling, Neurobiol Dis. mars, vol.9, issue.2, pp.220-253, 2002.

J. Ferrier, V. Pereira, J. Busserolles, N. Authier, and D. Balayssac, Emerging trends in understanding chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep, vol.17, p.364, 2013.

G. Santabarbara, P. Maione, A. Rossi, and C. Gridelli, Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy, Expert Opin Pharmacother, vol.17, issue.4, pp.561-70, 2016.

J. T. Hartmann and H. Lipp, Toxicity of platinum compounds, Expert Opin Pharmacother. juin, vol.4, issue.6, pp.889-901, 2003.

M. I. Koukourakis, Amifostine in clinical oncology: current use and future applications, Anticancer Drugs. mars, vol.13, issue.3, pp.181-209, 2002.

N. V. Aguilar-markulis, S. Beckley, R. Priore, and C. Mettlin, Auditory toxicity effects of longterm cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients, J Surg Oncol, vol.16, issue.2, pp.111-134, 1981.

M. J. Mckeage, Comparative adverse effect profiles of platinum drugs. Drug Saf, vol.13, pp.228-272, 1995.

M. Kobayashi, H. To, A. Tokue, A. Fujimura, and E. Kobayashi, Cisplatin-induced vomiting depends on circadian timing, Chronobiol Int. sept, vol.18, issue.5, pp.851-63, 2001.

L. B. Travis, E. J. Holowaty, K. Bergfeldt, C. F. Lynch, B. A. Kohler et al., Risk of leukemia after platinum-based chemotherapy for ovarian cancer, N Engl J Med. 4 févr, vol.340, issue.5, pp.351-358, 1999.

A. Gerl, D. Mühlbayer, G. Hansmann, W. Mraz, and W. Hiddemann, The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors, Cancer. 1 avr, vol.91, issue.7, pp.1297-303, 2001.

E. Reed, S. H. Yuspa, L. A. Zwelling, R. F. Ozols, and M. C. Poirier, Quantitation of cisdiamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy, J Clin Invest. févr, vol.77, issue.2, pp.545-50, 1986.

A. A. Argyriou, J. Bruna, P. Marmiroli, and G. Cavaletti, Chemotherapy-induced peripheral neurotoxicity (CIPN): an update, Crit Rev Oncol Hematol. avr, vol.82, issue.1, pp.51-77, 2012.

J. S. Gill and A. J. Windebank, Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle, J Clin Invest. 15 juin, vol.101, issue.12, pp.2842-50, 1998.

D. Wang and S. J. Lippard, Cellular processing of platinum anticancer drugs, Nat Rev Drug Discov. avr, vol.4, issue.4, pp.307-327, 2005.

W. Grisold, G. Cavaletti, and A. J. Windebank, Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention, Neuro-Oncol. sept, vol.14, issue.4, pp.45-54, 2012.

A. A. Argyriou, A. P. Kyritsis, T. Makatsoris, and H. P. Kalofonos, Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature, Cancer Manag Res, vol.6, pp.135-182, 2014.

A. Dzagnidze, Z. Katsarava, J. Makhalova, B. Liedert, M. Yoon et al., Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy, J Neurosci Off J Soc Neurosci. 29 août, vol.27, issue.35, pp.9451-9458, 2007.

N. Kerckhove, C. A. Condé, S. Chaleteix, C. Pezet, D. Balayssac et al., Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review, Front Pharmacol, vol.8, p.86, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01682157

A. S. Jaggi and N. Singh, Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy, Toxicology. 27 janv, vol.291, issue.1-3, pp.1-9, 2012.

A. Krarup-hansen, S. Helweg-larsen, H. Schmalbruch, M. Rørth, and C. Krarup, Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies, Brain J Neurol. avr, vol.130, pp.1076-88, 2007.

G. Gutiérrez-gutiérrez, M. Sereno, A. Miralles, E. Casado-sáenz, and E. Gutiérrez-rivas, Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies, Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. févr, vol.12, issue.2, pp.81-91, 2010.

G. M. Higa, T. C. Wise, and E. B. Crowell, Severe, disabling neurologic toxicity following cisplatin retreatment, Ann Pharmacother. févr, vol.29, issue.2, pp.134-141, 1995.

S. W. Thompson, L. E. Davis, M. Kornfeld, R. D. Hilgers, and J. C. Standefer, Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies, Cancer, vol.54, issue.7, pp.1269-75, 1984.

V. Chaudhry, M. Chaudhry, T. O. Crawford, E. Simmons-o'brien, and J. W. Griffin, Toxic neuropathy in patients with pre-existing neuropathy, Neurology. 28 janv, vol.60, issue.2, pp.337-377, 2003.

M. B. Hansen, The enteric nervous system III: a target for pharmacological treatment, Pharmacol Toxicol. juill, vol.93, issue.1, pp.1-13, 2003.

R. Eeles, D. M. Tait, and M. J. Peckham, Lhermitte's sign as a complication of cisplatincontaining chemotherapy for testicular cancer, Cancer Treat Rep. juill, vol.70, issue.7, pp.905-912, 1986.

I. Qaddoumi, J. K. Bass, J. Wu, C. A. Billups, A. W. Wozniak et al., Carboplatinassociated ototoxicity in children with retinoblastoma, J Clin Oncol Off J Am Soc Clin Oncol. 1 avr, vol.30, issue.10, pp.1034-1075, 2012.

G. K. Prithviraj, K. Baksh, W. Fulp, K. Meredith, S. Hoffe et al., Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer, Dis Esophagus Off J Int Soc Dis Esophagus. déc, vol.28, issue.8, pp.782-789, 2015.

A. A. Argyriou, P. Polychronopoulos, G. Iconomou, A. Koutras, H. P. Kalofonos et al., Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies, J Neurol. déc, vol.252, issue.12, pp.1459-64, 2005.

B. Desoize and C. Madoulet, Particular aspects of platinum compounds used at present in cancer treatment, Crit Rev Oncol Hematol. juin, vol.42, issue.3, pp.317-342, 2002.

J. T. Hartmann, L. M. Fels, A. Franzke, S. Knop, M. Renn et al., Comparative study of the acute nephrotoxicity from standard dose cisplatin +/-ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide, Anticancer Res, vol.20, issue.5C, pp.3767-73, 2000.

M. L. De-lemos, Application of the area under the curve of carboplatin in predicting toxicity and efficacy, Cancer Treat Rev. déc, vol.24, issue.6, pp.407-421, 1998.

O. Heinzlef, J. P. Lotz, and E. Roullet, Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy, J Neurol Neurosurg Psychiatry. mai, vol.64, issue.5, pp.667-676, 1998.

C. Schulze, M. Mcgowan, S. Jordt, and B. E. Ehrlich, Prolonged oxaliplatin exposure alters intracellular calcium signaling: a new mechanism to explain oxaliplatin-associated peripheral neuropathy, Clin Colorectal Cancer. juin, vol.10, issue.2, pp.126-159, 2011.

A. A. Argyriou, P. Polychronopoulos, G. Iconomou, E. Chroni, and H. P. Kalofonos, A review on oxaliplatin-induced peripheral nerve damage, Cancer Treat Rev. juin, vol.34, issue.4, pp.368-77, 2008.

G. Cavaletti, G. Tredici, M. G. Petruccioli, E. Dondè, P. Tredici et al., Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat, Eur J Cancer Oxf Engl, vol.37, issue.18, pp.2457-63, 1990.

T. Alcindor and N. Beauger, Oxaliplatin: a review in the era of molecularly targeted therapy, Curr Oncol Tor Ont. janv, vol.18, issue.1, pp.18-25, 2011.

D. Simpson, C. Dunn, M. Curran, and K. L. Goa, Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer, Drugs, vol.63, pp.2127-56, 2003.

C. Tournigand, F. Maindrault-goebel, C. Louvet, A. De-gramont, and M. Krulik, Severe anaphylactic reactions to oxaliplatin, Eur J Cancer Oxf Engl, vol.34, issue.8, pp.1297-1305, 1990.

F. Grolleau, L. Gamelin, M. Boisdron-celle, B. Lapied, M. Pelhate et al., A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltagegated sodium channels, J Neurophysiol. mai, vol.85, issue.5, pp.2293-2300, 2001.

T. Andre, C. Boni, and L. Mounedji-boudiaf, Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer, Cancer Treat Rev. déc, vol.350, issue.8, pp.711-714, 2004.

E. Brouwers, A. Huitema, W. Boogerd, J. H. Beijnen, and J. Schellens, Persistent neuropathy after treatment with cisplatin and oxaliplatin, Acta Oncol Stockh Swed, vol.48, issue.6, pp.832-873, 2009.

A. Pietrangeli, M. Leandri, E. Terzoli, B. Jandolo, and C. Garufi, Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up, Eur Neurol, vol.56, issue.1, pp.13-19, 2006.

A. G. Dimitrov and N. A. Dimitrova, A possible link of oxaliplatin-induced neuropathy with potassium channel deficit, Muscle Nerve. mars, vol.45, issue.3, pp.403-414, 2012.

R. Velasco and J. Bruna, Taxane-Induced Peripheral Neurotoxicity, Toxics. 28 avr, vol.3, issue.2, pp.152-69, 2015.

T. M. Mekhail and M. Markman, Paclitaxel in cancer therapy, Expert Opin Pharmacother. juin, vol.3, issue.6, pp.755-66, 2002.

L. C. Pronk, G. Stoter, and J. Verweij, Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects, Cancer Treat Rev. sept, vol.21, issue.5, pp.463-78, 1995.

D. Cella, A. Peterman, S. Hudgens, K. Webster, and M. A. Socinski, Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACTtaxane), Cancer. 15 août, vol.98, issue.4, pp.822-853, 2003.

E. A. Eisenhauer, W. W. Huinink, K. D. Swenerton, L. Gianni, J. Myles et al., European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion, J Clin Oncol Off J Am Soc Clin Oncol. déc, vol.12, issue.12, pp.2654-66, 1994.

P. Della-torre, A. R. Imondi, C. Bernardi, A. Podestà, D. Moneta et al., Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel, Cancer Chemother Pharmacol, vol.44, issue.2, pp.138-180, 1999.

E. K. Rowinsky, E. A. Eisenhauer, V. Chaudhry, S. G. Arbuck, and R. C. Donehower, Clinical toxicities encountered with paclitaxel (Taxol), Semin Oncol. août, vol.20, issue.4, pp.1-15, 1993.

E. K. Rowinsky, V. Chaudhry, D. R. Cornblath, and R. C. Donehower, Neurotoxicity of Taxol. J Natl Cancer Inst Monogr, issue.15, pp.107-122, 1993.

J. P. Guastalla and V. Diéras, The taxanes: toxicity and quality of life considerations in advanced ovarian cancer, Br J Cancer. déc, vol.89, issue.3, pp.16-22, 2003.

A. H. Zedan and O. J. Vilholm, Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires, Basic Clin Pharmacol Toxicol. août, vol.115, issue.2, pp.193-200, 2014.

S. Jain and L. T. Vahdat, Eribulin mesylate, Clin Cancer Res Off J Am Assoc Cancer Res, vol.17, issue.21, pp.6615-6637, 2011.

A. A. Argyriou, M. Koltzenburg, P. Polychronopoulos, S. Papapetropoulos, and H. P. Kalofonos, Peripheral nerve damage associated with administration of taxanes in patients with cancer, Crit Rev Oncol Hematol. juin, vol.66, issue.3, pp.218-246, 2008.

S. Park, C. Wu, J. D. Gordon, X. Zhong, A. Emami et al., Taxol induces caspase-10-dependent apoptosis, J Biol Chem. 3 déc, vol.279, issue.49, pp.51057-67, 2004.

C. L. Loprinzi, B. N. Reeves, S. R. Dakhil, J. A. Sloan, S. L. Wolf et al., Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1, J Clin Oncol Off J Am Soc Clin Oncol. 10 avr, vol.29, issue.11, pp.1472-1480, 2011.

C. Tofthagen, R. D. Mcallister, and C. Visovsky, Peripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptoms, J Adv Pract Oncol. juill, vol.4, issue.4, pp.204-219, 2013.

K. Osmani, S. Vignes, M. Aissi, F. Wade, P. Milani et al., Taxane-induced peripheral neuropathy has good long-term prognosis: a 1-to 13-year evaluation, J Neurol. sept, vol.259, issue.9, pp.1936-1979, 2012.

M. Markman, Managing taxane toxicities. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, mars, vol.11, issue.3, pp.144-151, 2003.

S. E. Jones, J. Erban, B. Overmoyer, G. T. Budd, L. Hutchins et al., Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer, J Clin Oncol Off J Am Soc Clin Oncol. 20 août, vol.23, issue.24, pp.5542-51, 2005.

F. De-iuliis, L. Taglieri, G. Salerno, R. Lanza, and S. Scarpa, Taxane induced neuropathy in patients affected by breast cancer: Literature review, Crit Rev Oncol Hematol, vol.96, issue.1, pp.34-45, 2015.

A. Kruczynski and B. T. Hill, Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties, Crit Rev Oncol Hematol, vol.40, issue.2, pp.159-73, 2001.

E. Mora, E. Smith, C. Donohoe, and D. L. Hertz, Vincristine-induced peripheral neuropathy in pediatric cancer patients, Am J Cancer Res, vol.6, issue.11, pp.2416-2446, 2016.

R. Said and A. M. Tsimberidou, Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies, Expert Opin Drug Metab Toxicol. mars, vol.10, issue.3, pp.483-94, 2014.

N. Okada, T. Hanafusa, T. Sakurada, K. Teraoka, T. Kujime et al., Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy, J Clin Med Res. août, vol.6, issue.4, pp.252-60, 2014.

A. Moore and R. Pinkerton, Vincristine: Can its therapeutic index be enhanced? Pediatr Blood Cancer. 15 déc, vol.53, pp.1180-1187, 2009.
DOI : 10.1002/pbc.22161

L. Yang, L. Yu, X. Chen, Y. Hu, and B. Wang, Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia, Med Sci Monit Int Med J Exp Clin Res. 7 juin, vol.21, pp.1656-61, 2015.

S. Lobert, B. Vulevic, and J. J. Correia, Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine, Biochemistry. 28 mai, vol.35, issue.21, pp.6806-6820, 1996.

N. Haim, R. Epelbaum, M. Ben-shahar, D. Yarnitsky, W. Simri et al., Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas, Cancer. 15 mai, vol.73, issue.10, pp.2515-2524, 1994.

G. Pérez, P. Serrano-pozo, A. Franco-macías, E. Montes-latorre, E. Gómez-aranda et al., Vincristine-induced acute neurotoxicity versus Guillain-Barré syndrome: a diagnostic dilemma, Eur J Neurol. juill, vol.14, issue.7, pp.826-834, 2007.

M. Qweider, J. M. Gilsbach, and V. Rohde, Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report, J Neurosurg Spine. mars, vol.6, issue.3, pp.280-283, 2007.
DOI : 10.3171/spi.2007.6.3.280

L. S. Gilchrist, L. R. Tanner, and K. K. Ness, Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer. Pediatr Blood Cancer, janv, vol.64, issue.1, pp.180-187, 2017.

J. San-miguel, J. Bladé, M. Boccadoro, J. Cavenagh, A. Glasmacher et al., A practical update on the use of bortezomib in the management of multiple myeloma, The Oncologist. janv, vol.11, issue.1, pp.51-61, 2006.

A. A. Argyriou, G. Iconomou, and H. P. Kalofonos, Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature, Blood. 1 sept, vol.112, issue.5, pp.1593-1602, 2008.

G. Jackson, H. Einsele, P. Moreau, and J. S. Miguel, Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies, Cancer Treat Rev. déc, vol.31, issue.8, pp.591-602, 2005.

N. C. Miltenburg and W. Boogerd, Chemotherapy-induced neuropathy: A comprehensive survey, Cancer Treat Rev. août, vol.40, issue.7, pp.872-82, 2014.
DOI : 10.1016/j.ctrv.2014.04.004

A. Badros, O. Goloubeva, J. S. Dalal, I. Can, J. Thompson et al., Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature, Cancer. 1 sept, vol.110, issue.5, pp.1042-1051, 2007.

C. Cioroiu and L. H. Weimer, Update on Chemotherapy-Induced Peripheral Neuropathy, Curr Neurol Neurosci Rep. juin, vol.17, issue.6, p.47, 2017.
DOI : 10.1007/s11910-017-0757-7

B. Mohty, J. El-cheikh, I. Yakoub-agha, P. Moreau, J. Harousseau et al., Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations, Haematologica. févr, vol.95, issue.2, pp.311-320, 2010.
DOI : 10.3324/haematol.2009.012674

URL : http://www.haematologica.org/content/95/2/311.full.pdf

S. K. Teo, D. I. Stirling, and J. B. Zeldis, Thalidomide as a novel therapeutic agent: new uses for an old product, Drug Discov Today. 15 janv, vol.10, issue.2, pp.107-121, 2005.

A. Mazumder and S. Jagannath, Thalidomide and lenalidomide in multiple myeloma, Best Pract Res Clin Haematol, vol.19, issue.4, pp.769-80, 2006.

P. Tosi, E. Zamagni, C. Cellini, R. Plasmati, D. Cangini et al., Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma, Eur J Haematol. mars, vol.74, issue.3, pp.212-218, 2005.

C. Sioka and A. P. Kyritsis, Central and peripheral nervous system toxicity of common chemotherapeutic agents, Cancer Chemother Pharmacol. avr, vol.63, issue.5, pp.761-768, 2009.

I. M. Ghobrial and S. V. Rajkumar, Management of thalidomide toxicity, J Support Oncol, vol.1, issue.3, pp.194-205, 2003.

M. Banach, J. K. Juranek, and A. L. Zygulska, Chemotherapy-induced neuropathies-a growing problem for patients and health care providers, Brain Behav, vol.7, issue.1, p.558, 2017.

A. Corso, P. Zappasodi, L. Barbarano, M. T. Petrucci, A. Palumbo et al., Longterm outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects, Leuk Res. sept, vol.33, issue.9, pp.145-149, 2009.

L. Peng, Y. Hong, X. Ye, P. Shi, J. Zhang et al., Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis, Oncotarget. 19 déc, vol.8, issue.67, pp.112076-84, 2017.

M. Paillard, E. Curtit, E. Dobi, L. Mansi, F. Bazan et al.,

, Bull Cancer (Paris). sept, vol.102, issue.9, pp.737-785, 2015.

L. T. Vahdat, A. A. Garcia, C. Vogel, C. Pellegrino, D. L. Lindquist et al., Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy, Breast Cancer Res Treat. juill, vol.140, issue.2, pp.341-51, 2013.

M. K. Doherty and P. G. Morris, Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy, Int J Womens Health, vol.7, pp.47-58, 2015.

P. C. Jimenez, D. V. Wilke, and L. V. Costa-lotufo, Marine drugs for cancer: surfacing biotechnological innovations from the oceans. Clin Sao Paulo Braz, vol.20, p.482, 2018.

K. M. Wozniak, K. Nomoto, R. G. Lapidus, Y. Wu, V. Carozzi et al., Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice, Cancer Res. 1 juin, vol.71, issue.11, pp.3952-62, 2011.

N. E. Lapointe, G. Morfini, S. T. Brady, S. C. Feinstein, L. Wilson et al., Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy, Neurotoxicology. juill, vol.37, pp.231-240, 2013.

D. L. Hershman, J. M. Unger, K. D. Crew, L. M. Minasian, D. Awad et al., Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy, J Clin Oncol Off J Am Soc Clin Oncol. 10 juill, vol.31, issue.20, pp.2627-2660, 2013.

D. L. Hershman, J. M. Unger, K. D. Crew, C. Till, H. Greenlee et al., TwoYear Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715), J Natl Cancer Inst. 18 janv, 2018.

A. D. Leal, R. Qin, P. J. Atherton, P. Haluska, R. J. Behrens et al., North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, doubleblind, placebo-controlled study, Cancer. 15 juin, vol.120, issue.12, pp.1890-1897, 2014.

P. Lin, M. Lee, W. Wang, Y. , C. Chao et al., N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. mai, vol.14, issue.5, pp.484-491, 2006.

L. A. Kottschade, J. A. Sloan, M. A. Mazurczak, D. B. Johnson, B. P. Murphy et al., The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.19, pp.1769-77, 2011.

H. Huang, M. He, L. Liu, and L. Huang, Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy: a meta-analysis, Contemp Oncol Poznan Pol, vol.20, issue.3, pp.237-278, 2016.

Z. Salehi and M. Roayaei, Effect of Vitamin E on Oxaliplatin-induced Peripheral Neuropathy Prevention: A Randomized Controlled Trial, Int J Prev Med, vol.6, p.104, 2015.

S. Koeppen, C. Verstappen, R. Körte, M. E. Scheulen, D. Strumberg et al., Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma, J Cancer Res Clin Oncol. mars, vol.130, issue.3, pp.153-60, 2004.

R. G. Van-der-hoop, C. J. Vecht, M. E. Van-der-burg, A. Elderson, W. Boogerd et al., Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer, N Engl J Med. 11 janv, vol.322, issue.2, pp.89-94, 1990.

J. A. Roberts, E. L. Jenison, K. Kim, D. Clarke-pearson, and A. Langleben, A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer, Gynecol Oncol, vol.67, issue.2, pp.172-179, 1997.

D. Loven, H. Levavi, G. Sabach, R. Zart, M. Andras et al., Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel, Eur J Cancer Care (Engl). janv, vol.18, issue.1, pp.78-83, 2009.

W. Wang, J. Lin, T. Lin, W. Chen, J. Jiang et al., Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients, The Oncologist. mars, vol.12, issue.3, pp.312-321, 2007.

A. S. , Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy, Ann Pharmacother. oct, vol.42, issue.10, pp.1481-1486, 2008.

Z. Ghoreishi, A. Esfahani, A. Djazayeri, M. Djalali, B. Golestan et al., Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial, BMC Cancer. 15 août, vol.12, p.355, 2012.

A. Esfahani, M. H. Somi, H. Ayromlou, A. Nikanfar, M. A. Jafarabadi et al., The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial, Biomark Res, vol.4, p.13, 2016.

Ó. Arrieta, N. Hernández-pedro, M. C. Fernández-gonzález-aragón, D. Saavedra-pérez, A. D. Campos-parra et al., Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer, Neurology. 6 sept, vol.77, issue.10, pp.987-95, 2011.

M. Nishioka, M. Shimada, N. Kurita, T. Iwata, S. Morimoto et al., The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen, Int J Clin Oncol. août, vol.16, issue.4, pp.322-329, 2011.

E. Oki, Y. Emi, H. Kojima, J. Higashijima, T. Kato et al., Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study, Int J Clin Oncol. août, vol.20, issue.4, pp.767-75, 2015.

T. Kono, T. Hata, S. Morita, Y. Munemoto, T. Matsui et al., Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy, Cancer Chemother Pharmacol. déc, vol.72, issue.6, pp.1283-90, 2013.

L. Gamelin, M. Boisdron-celle, R. Delva, V. Guérin-meyer, N. Ifrah et al., Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer, Clin Cancer Res Off J Am Assoc Cancer Res. 15 juin, vol.10, issue.12, pp.4055-61, 2004.

H. S. Hochster, A. Grothey, and B. H. Childs, Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity, J Clin Oncol Off J Am Soc Clin Oncol. 1 sept, vol.25, issue.25, pp.4028-4037, 2007.

W. Chay, S. Tan, Y. Lo, S. Ong, H. Ng et al., Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy, Asia Pac J Clin Oncol. déc, vol.6, issue.4, pp.270-277, 2010.

A. Grothey, D. A. Nikcevich, J. A. Sloan, J. W. Kugler, P. T. Silberstein et al., Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7, J Clin Oncol Off J Am Soc Clin Oncol. 1 févr, vol.29, issue.4, pp.421-428, 2011.

C. L. Loprinzi, R. Qin, S. R. Dakhil, L. Fehrenbacher, K. A. Flynn et al., Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance), J Clin Oncol Off J Am Soc Clin Oncol. 1 avr, vol.32, issue.10, pp.997-1005, 2014.

B. Jordan, F. Jahn, J. Beckmann, S. Unverzagt, C. Müller-tidow et al., Calcium and Magnesium Infusions for the Prevention of Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review, Oncology, vol.90, issue.6, pp.299-306, 2016.

F. Hilpert, A. Stähle, O. Tomé, A. Burges, D. Rossner et al., Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.13, pp.797-805, 2005.

I. D. Davis, L. Kiers, L. Macgregor, M. Quinn, J. Arezzo et al., A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy, Clin Cancer Res Off J Am Assoc Cancer Res. 1 mars, vol.11, issue.5, pp.1890-1898, 2005.

S. Von-delius, F. Eckel, S. Wagenpfeil, M. Mayr, K. Stock et al., Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study, Invest New Drugs. avr, vol.25, issue.2, pp.173-80, 2007.

S. S. Shinde, D. Seisler, G. Soori, P. J. Atherton, D. R. Pachman et al., Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. févr, vol.24, issue.2, pp.547-53, 2016.

P. L. Mitchell, D. Goldstein, M. Michael, P. Beale, M. Friedlander et al., Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatininduced neurotoxicity, Clin Colorectal Cancer. juill, vol.6, issue.2, pp.146-51, 2006.

D. C. De-andrade, J. Teixeira, M. Galhardoni, R. Ferreira, K. et al., Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial. The Oncologist, vol.22, pp.1154-105, 2017.

A. Kautio, M. Haanpää, A. Leminen, E. Kalso, H. Kautiainen et al., Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms, Anticancer Res. juill, vol.29, issue.7, pp.2601-2607, 2009.

J. E. Hammack, J. C. Michalak, C. L. Loprinzi, J. A. Sloan, P. J. Novotny et al., Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy, Pain. juill, vol.98, issue.1-2, pp.195-203, 2002.

T. Kus, G. Aktas, G. Alpak, M. E. Kalender, A. Sevinc et al., Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a singlecenter retrospective case-control study, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. mai, vol.24, issue.5, pp.2085-91, 2016.

J. P. Durand, G. Deplanque, V. Montheil, J. M. Gornet, F. Scotte et al., Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial, Ann Oncol Off J Eur Soc Med Oncol. janv, vol.23, issue.1, pp.200-205, 2012.

C. Zimmerman, P. J. Atherton, D. Pachman, D. Seisler, N. Wagner-johnston et al., MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. mars, vol.24, issue.3, pp.1071-1079, 2016.

Y. Hirayama, K. Ishitani, Y. Sato, S. Iyama, K. Takada et al., Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial, Int J Clin Oncol, vol.20, issue.5, pp.866-71, 2015.

E. Smith, H. Pang, C. Cirrincione, S. Fleishman, E. D. Paskett et al., Effect of duloxetine on pain, function, and quality of life among patients with chemotherapyinduced painful peripheral neuropathy: a randomized clinical trial, JAMA. 3 avr, vol.309, issue.13, pp.1359-67, 2013.

E. Battaglini, S. B. Park, E. H. Barnes, and D. Goldstein, A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy, Contemp Clin Trials. juill, vol.70, pp.135-143, 2018.

J. Wang, Q. Li, B. Xu, T. Zhang, S. Chen et al., Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy, Chin J Cancer Res Chung, vol.29, issue.5, pp.411-419, 2017.

A. Kautio, M. Haanpää, T. Saarto, and E. Kalso, Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms, J Pain Symptom Manage. janv, vol.35, issue.1, pp.31-40, 2008.

R. D. Rao, J. C. Michalak, J. A. Sloan, C. L. Loprinzi, G. S. Soori et al., Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer, vol.110, pp.2110-2118, 2007.

M. W. Saif, K. Syrigos, K. Kaley, and I. Isufi, Role of pregabalin in treatment of oxaliplatininduced sensory neuropathy, Anticancer Res. juill, vol.30, issue.7, pp.2927-2960, 2010.

R. D. Rao, P. J. Flynn, J. A. Sloan, G. Y. Wong, P. Novotny et al., Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer. 15 juin, vol.112, issue.12, pp.2802-2810, 2008.

D. L. Barton, E. J. Wos, R. Qin, B. I. Mattar, N. B. Green et al., A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, juin, vol.19, issue.6, pp.833-874, 2011.

M. T. Fallon, D. J. Storey, A. Krishan, C. J. Weir, R. Mitchell et al., Cancer treatment-related neuropathic pain: proof of concept study with menthol--a TRPM8 agonist, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. sept, vol.23, issue.9, pp.2769-77, 2015.

I. Filipczak-bryniarska, R. M. Krzyzewski, J. Kucharz, A. Michalowska-kaczmarczyk, J. Kleja et al., High-dose 8% capsaicin patch in treatment of chemotherapyinduced peripheral neuropathy: single-center experience, Med Oncol Northwood Lond Engl. 17 août, vol.34, issue.9, p.162, 2017.

M. E. Lynch, P. Cesar-rittenberg, and A. G. Hohmann, A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain, J Pain Symptom Manage. janv, vol.47, issue.1, pp.166-73, 2014.

J. Schloss, M. Colosimo, and L. Vitetta, New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy, Asia-Pac J Oncol Nurs. mars, vol.3, issue.1, pp.73-85, 2016.

D. R. Pachman, T. Dockter, P. J. Zekan, B. Fruth, K. J. Ruddy et al., A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.25, pp.3407-3423, 2017.

A. Hanai, H. Ishiguro, T. Sozu, M. Tsuda, I. Yano et al., Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial, J Natl Cancer Inst. 1 févr, vol.110, issue.2, pp.141-149, 2018.

C. Brami, T. Bao, and G. Deng, Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review, Crit Rev Oncol Hematol. févr, vol.98, pp.325-359, 2016.

G. Franconi, L. Manni, S. Schröder, P. Marchetti, and N. Robinson, A systematic review of experimental and clinical acupuncture in chemotherapy-induced peripheral neuropathy. Evid-Based, Complement Altern Med ECAM, p.516916, 2013.